Drugs / SB-649868
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT01299597 | Jan → Feb 2010 | sleep disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01030939 | Aug 2009 → Jan 2010 | sleep disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00534872 | Oct 2007 | insomnia | GlaxoSmithKline | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT00520663 | Jun → Aug 2007 | sleep disorder, initiating and maintaining sleep | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00495729 | Apr → Aug 2007 | sleep disorder, initiating and maintaining sleep | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00440323 | Jan → Jul 2007 | sleep disorder, initiating and maintaining sleep | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00426816 | Dec 2006 → May 2007 | sleep disorder, initiating and maintaining sleep | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SB-649868 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00534872 ↗ |
| Known as | GSK649868 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1272307 ↗ |
| Action | Inhibit | “dual orexin receptor antagonist SB-649868” PMID 22237311 ↗ Jan 2012 |
| Modality | Small molecule | — CHEMBL1272307 ↗ |
| Route | Oral | “Single Oral Doses of SB-649868 and of Zolpidem” NCT00440323 ↗ |
| Target | CYP3A4 | “enzyme inhibition effects of SB-649868 on CYP3A4” NCT01299597 ↗ |
| Target | HCRTR1 | “Orexin receptor 1 antagonist” CHEMBL1272307 ↗ |
| Target | HCRTR2 | “Orexin receptor 2 antagonist” CHEMBL1272307 ↗ |